Probiotics and Biomarkers in Irritable Bowel Syndrome

The goal of this double-blind parallel-arm randomized controlled trial is to learn if a probiotic supplement (containing a new strain derived from L. reuteri) alters outcomes related to symptom severity and transit time in adults with irritable bowel syndrome (IBS). The main question it aims to answer is: Does the probiotic alter IBS symptom severity? Researchers will compare the probiotic to a placebo (a lookalike substance that contains no probiotic) to see if the probiotic works to alter outcomes. Participants will: Be randomized to either take the probiotic supplement or placebo supplement daily for 12 weeks. Visit the lab for 4 study visits (visit 1: screening and informed consent; visit 2: randomization, data collection, beginning the intervention; visit 3: end of intervention and data collection; visit 4: 3 month post intervention follow up and data collection). Provide biological samples (blood, stool, saliva, urine) Complete questionnaires

NCT Number	NCT07584278
Lead Sponsor	Sahlgrenska University Hospital
Conditions	Irritable Bowel Syndrome (IBS)
Enrollment	252 participants
Start Date	2026-04-28
Primary Completion	2031-04 (estimated)
Study Completion	2031-05 (estimated)
Updated on ClinicalTrials.gov	2026-06-01